±èÀºÃ¶ °¡Å縯´ëÇб³ ºÎõ¼º¸ðº´¿ø ¾È°ú ±èÀºÃ¶ ±³¼ö°¡ Áö³ 9¿ù 1ÀÏ °³ÃÖµÈ 2024 Çѱ¹°Ç¼º¾ÈÇÐȸ Dry eye academy¿¡¼ ¡®KDESÃÖ¿ì¼ö Çмú»ó¡¯À» ¼ö»óÇÏ¿´´Ù.
°¡Å縯´ëÇб³ ºÎõ¼º¸ðº´¿ø ¾È°ú ±èÀºÃ¶ ±³¼ö
Çѱ¹°Ç¼º¾ÈÇÐȸ´Â ÃÖ±Ù ±Þ¼Óµµ·Î Áõ°¡ÇÏ°í ÀÖ´Â ¾È±¸°ÇÁ¶ÁõÀ» Æ÷ÇÔÇÑ ´«¹°ÁúȯÀ» ¿¬±¸ÇÏ´Â ¾È°ú ÀÇ»çµéÀÇ Àü¹® Çмú´Üü·Î¼, ¾Æ½Ã¾ÆÁö¿ª ¿©·¯ ±¹°¡µéÀÇ °Ç¼º¾ÈÇÐȸ¿Í ³×Æ®¿öÅ©¸¦ Çü¼ºÇÏ°í ÀÖÀ¸¸ç, ±¹¹Î ´« °Ç°°ú °ü·Ã ½Å¾à ¹× ÀÇ·á±â±â °³¹ß¿¡ ±â¿©ÇÏ°í ÀÖ´Ù.
±èÀºÃ¶ ±³¼ö´Â ¡®Comparision of matrix metallopeptidase-9 expression following cyclosporine and diquafosol treatment in dry eye(°ÇÁ¶Áõ ȯÀÚ¿¡¼ »çÀÌŬ·Î½ºÆ÷¸°°ú µðÄí¾ÆÆ÷¼Ö Ä¡·á ÈÄ ¸ÅÆ®¸¯½º ¸ÞÅ»·ÎÆéƼ´Ù¾ÆÁ¦-9 ¹ßÇö ºñ±³ ¿¬±¸)¡¯¶õ ÁÖÁ¦·Î ÃÖ¿ì¼ö Çмú»óÀ» ¼ö»óÇß´Ù.
ÇÑÆí ±èÀºÃ¶ ±³¼ö´Â Áö³ 2017³â ¹Ì±¹ ¹é³»Àå ±¼ÀýÇÐȸ(ASCRS, American Society of Cataract and Refractive Surgery)¿¡¼ ÃÖ¿ì¼ö ±¸¿¬»óÀ», 2018³â Á¦31ȸ ¾Æ½Ã¾Æ-ÅÂÆò¾ç ¹é³»Àå&±¼Àý¼ö¼úÇÐȸ(APACRS)¿¡¼ ÀÌÆ÷½ºÅÍ ºÎ¹® ÃÖ¿ì¼ö»óÀ», 2019³â ¡®Á¦122ȸ ´ëÇѾȰúÇÐȸ Çмú´ëȸ¡¯¿¡¼ ¼¼±¤Çмú»ó ±Ý»óÀ» ¼ö»óÇÏ´Â µî ¶Ù¾î³ ¿¬±¸¾÷ÀûÀ¸·Î ¿©·¯ ¾È°úÇÐȸ ¼ö»óÀ» À̾°í ÀÖ´Ù.